SK Biopharm signs XCOPRI supply contract
에스케이바이오팜
326030
Signal Score
Historical Avg Return (5d)
+0.11%
Data Coverage
100%n=757
Risk-adjusted indicator based on 757 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Contract Amount: 41.61 Billion KRW (USD 27.60 Million)
- • Percentage of Recent Revenue: 5.9%
- • Recent Revenue (2025): 706.74 Billion KRW
- • Contract Duration: 1 day (May 27, 2026 - May 28, 2026)
AI Analysis Summary
SK Biopharmaceuticals Co., Ltd. signed a supply contract for its epilepsy drug, cenobamate (XCOPRI®), with its US subsidiary, SK Life Science, Inc. The contract is valued at 41.61 billion KRW (USD 27.60 million), representing 5.9% of the company's 2025 consolidated revenue of 706.74 billion KRW. This is an internal transaction for US market sales and will not be recognized as revenue on the consolidated financial statements. The contract period is from May 27, 2026, to May 28, 2026.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.